Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 6 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| NEKTAR THERAPEUTICS | 312,905 | reported | 16 May 2022 | tx 187+4,118,483−2,453,793 |
| ACELYRIN, Inc. | 150,000 | reported | 31 Aug 2024 | tx 5+1,485,257 |
| Septerna, Inc. | 125,000 | reported | 06 Feb 2026 | tx 8+424,500 |
| Rezolute, Inc. | 55,500 | reported | 19 Nov 2025 | tx 11+307,762 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 06 Feb 2026 | GRANT_AWARD | Septerna, Inc. | 125,000 | 0.00 USD | deriv |
| 19 Nov 2025 | GRANT_AWARD | Rezolute, Inc. | 21,000 | 0.00 USD | |
| 19 Nov 2025 | GRANT_AWARD | Rezolute, Inc. | 12,000 | 0.00 USD | deriv |
| 07 Aug 2025 | GRANT_AWARD | Septerna, Inc. | 37,500 | 0.00 USD | deriv |
| 10 Jun 2025 | GRANT_AWARD | Rezolute, Inc. | 9,000 | 0.00 USD | |
| 10 Jun 2025 | GRANT_AWARD | Rezolute, Inc. | 5,000 | 0.00 USD | deriv |
| 25 Feb 2025 | PURCHASE | Septerna, Inc. | 6,282 | 5.59 USD | |
| 27 Feb 2025 | PURCHASE | Septerna, Inc. | 3,718 | 5.85 USD | |
| 20 Feb 2025 | PURCHASE | Septerna, Inc. | 14,500 | 5.88 USD | |
| 21 Feb 2025 | PURCHASE | Septerna, Inc. | 5,000 | 5.85 USD | |
| 19 Feb 2025 | PURCHASE | Septerna, Inc. | 10,500 | 5.51 USD | first after silence |
| 16 Feb 2025 | GRANT_AWARD | Rezolute, Inc. | 25,500 | 0.00 USD | |
| 16 Feb 2025 | GRANT_AWARD | Rezolute, Inc. | 15,000 | 0.00 USD | deriv |
| 07 Feb 2025 | GRANT_AWARD | Septerna, Inc. | 222,000 | 0.00 USD | deriv |
| 31 Aug 2024 | GRANT_AWARD | ACELYRIN, Inc. | 150,000 | 0.00 USD | deriv |
| 23 May 2024 | GRANT_AWARD | ACELYRIN, Inc. | 184,042 | 0.00 USD | deriv |
| 23 Jan 2024 | GRANT_AWARD | Rezolute, Inc. | 30,000 | 0.00 USD | deriv |
| 09 Jan 2024 | GRANT_AWARD | ACELYRIN, Inc. | 855,513 | 0.00 USD | deriv |
| 04 Oct 2023 | OTHER | ACELYRIN, Inc. | 40,763 | 0.00 USD | |
| 17 Aug 2023 | GRANT_AWARD | ACELYRIN, Inc. | 254,939 | 0.00 USD | deriv |
| 23 Jun 2022 | GRANT_AWARD | Rezolute, Inc. | 80,000 | 0.00 USD | deriv |
| 15 May 2022 | GRANT_AWARD | NEKTAR THERAPEUTICS | 28,750 | 0.00 USD | |
| 16 May 2022 | SALE | NEKTAR THERAPEUTICS | 17,448 | 3.95 USD | |
| 04 May 2022 | PURCHASE | Rezolute, Inc. | 52,631 | 3.80 USD | |
| 16 Feb 2022 | SALE | NEKTAR THERAPEUTICS | 7,579 | 10.95 USD |
1 purchase reported after at least 12 months of silence — most recent on 19 Feb 2025.